<DOC>
	<DOCNO>NCT00530790</DOCNO>
	<brief_summary>This study design evaluate safety , pharmacokinetic profile efficacy Restless Legs Syndrome patient .</brief_summary>
	<brief_title>Clinical Evaluation Ropinirole CR-RLS ( SK &amp; F101468 ) Tablets Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>A subject consider eligible inclusion study follow criterion apply : At Week 1 ( start Screening period ) Patients diagnose RLS accord International RLS Study Group 's ( IRLSSG ) Diagnostic Criteria . Age : Patients age least 18 year 80 year . Patients RLS symptom even nighttime ( 17:00 7:00 next day ) least 20 day within one month start screen period . Patients treat RLS start Screening period meet criterion consider eligible previous therapy discontinue Screening period . Patients experience RLS symptom require treatment 17:00 prior bedtime . Gender : male female Female childbearing potential eligible inclusion study . However must negative pregnancy test Screening visit . They agree perform pregnancy test time determine practice one follow method contraception Screening visit till end followup examination . Abstinence Oral Contraceptive , either combined progestogen alone Injectable progestogen Implants levonorgestrel Estrogenic vaginal ring Percutaneous contraceptive patch Intrauterine device ( IUD ) intrauterine system ( IUS ) meet SOP effectiveness criterion state product label Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject Double barrier method : condom occlusive cap ( diaphragm cervical / vault cap ) plus spermicidal agent ( foam /gel / film / cream / suppository Inpatient outpatient status : Outpatient status Patients able give inform write consent person . For patient age 20 year , legally acceptable representative able give inform write consent . At Week 0 ( start treatment period ) Patients experience RLS symptom even nighttime ( 17:00 7:00 next day ) least 4 day within 7 day start treatment period . Patients sleep impairment associate RLS . Patients answer 3 ( severe ) 4 ( severe ) Question 4 ( Sleep disturbance ) IRLS Rating Scale Patients whose IRLS Rating Scale total score 15 point . Patients require treatment daytime RLS symptom ( 7:00 17:00 ) . Patients sign secondary RLS ( e.g . chronic renal failure , irondeficiency anemia , pregnancy , rheumatoid arthritis Parkinson 's disease ) . Patients whose serum ferritin level &lt; 10 μg/L ( ng/mL ) start Screening period . Patients follow sleep disorder associate RLS e.g . narcolepsy , sleep terror disorder , sleep walking disorder , breathe related sleep disorder ( Patients obvious apnea nighttime sleep alcohol drinking 15 times/hour use target apnea hypopnea index , case implement polysomnography ) , etc . Patients complication movement disorder ( e.g . Parkinson 's disease , dyskinesia , dystonia , etc. ) . Patients severe hepatic/renal/cardiac/pulmonary disorder hematopoietic disorder . The severity refers Grade 3 accord `` Classification Severity Adverse Experiences '' ( Pharmaceutical affair Bureau/Safety Division ( PAB/SD ) Notification No . 80 , date 29 June 1992 ) . Patients medical history complication cancer malignant tumour . Patients medical history complication substance abuse ( e.g . alcohol drug ) dependency substance last one year Patients whose diastolic blood pressure ( BP ) &gt; 110 mmHg &lt; 50 mmHg whose systolic BP &gt; 180 mmHg &lt; 90 mmHg start Screening period Week0 . Patients intolerant ropinirole hydrochloride ( HCl ) dopamine agonist . Patients medical history allergy ropinirole HCl past . Patients medical history Augmentation ropinirole HCl dopamine agonist past experienced early morning RLS symptom . Augmentation define : RLS appear 2 hour earlier pretreatment . Symptoms become severe pretreatment . Symptoms start less time rest treatment . The RLS extend site ( e.g . arm trunk ) . Patients without nighttime sleep habit ( e.g . nightshift worker , etc . ) must drastically change habitual bedtime study duration . Patients participate another clinical study investigational product medical device within last 12 week prior start screen period . Female patient pregnant lactating , may pregnant , plan pregnancy study . Patients chronic hepatitis typeB /or typeC positive hepatitis B surface antigen （HBsAg）and/or hepatitis C antibody . Patients medical condition , opinion investigator could affect efficacy safety assessment . This may include , limited follow disorder : diabetes , peripheral neuropathy , fibromyalgia syndrome , symptomatic orthostatic hypotension , hepatic renal failure , pleuropulmonary fibrosis . Patients receive treatment estrogen drug product drug know substantially inhibit CYP1A2 change dose baseline visit Week 0 . Others investigator ( sub investigator ) considers ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
</DOC>